💡After last Monday’s blackout… we’re back and ready for a new #PollOfTheWeek with a new leader of the initiative for the coming weeks... we welcome Isabel Garcia Fructuoso This time, she encourages us to talk about adjuvant treatment in triple-negative breast cancer. Here’s the

Muy feliz de haber recogido este premio en nombre de Olga Martínez-Sáez de esas mujeres que hacen que parezca fácil ser mujer en el mundo de la ciencia. Le debo muchas enseñanzas. Gracias, Yo Dona , por visibilizar a mujeres tan increíbles como ella.

YES! Isabel Garcia Fructuoso is now fully engaged with our POLL OF THE WEEK. Did you vote on our last poll? It was quite a controversial one🧐 Check out the results👇 #beSOLTI

And we are ready for the next #PollOfTheWeek!📊 Considering the positive preliminary results from the DESTINY-Breast09 trial, while awaiting final outcomes, would you currently favor using T-DXd plus pertuzumab as first-line treatment over standard THP (trastuzumab, pertuzumab,

Update from the #EMBER3 trial based on subgroup analysis 👀 at the curve in patients with co-mutated #ESR1 and #PIK3CA ESMO - Eur. Oncology #ESMObreast25

At the proffered papers session 1, Cristina Saura presents subgroup analyses from the EMBER-3: ✅ Imlunestrant + Abemaciclib consistently improves median PFS vs Imlunestrant monotherapy in the subgroup of patients pretreated with CDK4/6i #ESMOBreast25 #ESMOAmbassadors ESMO - Eur. Oncology

At #ESMOBreast25 Fedro Peccatori MD, PhD presents predictive factors of fertility in the POSITIVE trial 🤰🏼👶🏻 Lower age and no prior CT were associated with lower risk of low ovarian reserve (as expected); no association for type and duration of ET OncoAlert

🎥 HOY ha empezado #ESMOBreast25 | Cobertura diaria con #OncoBites 👩‍⚕️ Desde hoy, tres referentes en cáncer de mama te traen lo más destacado del congreso en tiempo real. 🩷 Avances clínicos, datos clave y lo que marcará el futuro de la oncología mamaria, contado al día. 🔗

Loved the discussion led by @DavidCescon at #ESMOBreast2025! Fully agree that for patients with access to T-DXd in 2L, capecitabine remains a very appealing 1L option—especially in the absence of rapid symptomatic progression.

So... What about DESTINY-Breast09? Did you answer this last week's poll? If you didn't, watch Dr. Isabel Garcia Fructuoso discuss the results. Comment with your thoughts! #beSOLTI #30aniversarioSOLTI

So... How do you feel after ESMOBreast? Are you ready to answser the next POLL OF THE WEEK WITH Dr. Isabel Garcia Fructuoso? 👇 In an HR+/HER2- patient who had a 24-month benefit from first-line CDK4/6 inhibitor plus aromatase inhibitor therapy and now presents with liver progression

📊 ¿Pertuzumab adyuvante para todos los HER2+? En #ESMOBREAST25, la Dra. Isabel Garcia Fructuoso revisa los datos a +11 años del estudio APHINITY. 🔹 ¿Beneficio sostenido en todos los subgrupos? 🔹 ¿Qué pacientes lo necesitan realmente tras cirugía? 💡 Una mirada crítica al uso

Very curious to see what everyone thinks while we wait for the ASCENT-04 data coming in the next few days… What would be your preferred first-line treatment in this setting? 👇👇👇👇👇🗳️🗳️🗳️

👏👏amazing 40m med PFS with TDXD+P v 20m THP. If 2L TDXD (DB03) is 28m PFS v 6m TDM1, does the maths favour 1L THP➡️2L TDXD? +add Palbo? Esp as 1L TDXD may make 2L TDM1 less effective (down reg HER2). Potentially 1L DB09 may ⬆️ CNS control. Def need OS - are some patients

So... are you all recovered from #ASCO25?👀 We are delighted to be back commenting our last POLL OF THE WEEK📊. Check out Dr. Isabel Garcia Fructuoso considerations regarding the results. Comment your thoughts!💬 We'll be back next week with our next poll, stay tuned! #beSOLTI

Start the post-congress week with a new POLL OF THE WEEK featuring Isabel Garcia Fructuoso! After the SERENA-6 plenary presentation at #ASCO25… In a patient with HR+/HER2− mBC receiving 1L AI + CDK4/6 inhibitor: what approach would you choose? A)👉Monitor ESR1 mutations and switch

In the last week's POLL OF THE WEEK we asked about SERENA-6 plenary presentation at #ASCO25📊 Dr. Isabel Garcia Fructuoso shares her comment on the results, write your thoughts below!💬 #beSOLTI

📊In this week's POLL OF THE WEEK with Dr. Isabel Garcia Fructuoso we are sharing a clinical case: 👩Patient with HER2+ breast cancer who started first-line treatment with T-DXd + pertuzumab, discontinued T-DXd due to toxicity and continued on PHESGO maintenance for over a year. Now

We never forget a poll. Not at all 😉 After the gala and the office opening… we’re back with this week’s POLL OF THE WEEK results! Dr. Isabel Garcia Fructuoso shares her take on the votes. What’s yours?💬 #beSOLTI

We’re kicking off the final POLL OF THE WEEK series featuring Dr. Isabel Garcia Fructuoso before the summer break! ☀️ ❓In a patient with HR+/HER2– breast cancer and a PIK3CA mutation who relapses with bone and liver metastases 10 months after completing adjuvant endocrine therapy with